The researchers hope these findings will help to guide clinicians when they are deciding whether to use benralizumab to treat patients with severe, uncontrolled, eosinophilic asthma.
Benralizumab is an anti-eosinophilic, anti-interleukin-5 receptor α monoclonal antibody. The Committee for Medicinal Products for Human Use recently adopted a positive opinion, recommending the granting of a marketing authorisation in EU for the treatment of severe eosinophilic asthma.